Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes

Journal of Internal Medicine

Volumn 256, Issue 2, 2004, Pages 119-127

  Leinonen, E S ^a   Hiukka, A ^a   Hurt Camejo, E ^b,c   Wiklund, O ^b   Sarna, S S ^a   Mattson Hulten L ^b   Westerbacka, J ^a   Salonen, R M ^d   Salonen, J T ^d,e   Taskinen, M R ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e Inner Savo Health Centre   (Finland)

Author keywords

CVD; Diabetes; Endothelium; Inflammation; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; COLONY STIMULATING FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; LIPOPROTEIN; PHOSPHOLIPASE A2; SERUM AMYLOID A; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL ACTIVATION; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ULTRASOUND;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; TUNICA INTIMA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 3242877119     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01350.x     Document Type: Article

References (40)

1. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998; 137 (Suppl.): S65-S73.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
3. Hurt-Camejo E, Olsson U, Wiklund W, Bondjers G, Camejo G. Cellular consequences of the association of Apo B lipoproteins with proteoglycans. Arterioscler Thromb Vasc Biol 1997; 17: 1011-7.
4. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nature Med 2002; 8: 1211-7.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
7. Hurt-Camejo E, Camejo G, Peilot H, Öörni K, Kovanen P. Phospholipase A2 in vascular disease. Circ Res 2001; 89: 298-304.
8. Barter PJ. Effects of inflammation on high-density lipoproteins. Arterioscler Thromb Vasc Biol 2002; 22: 1062-3.
9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
10. Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-8.
11. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5: 551-9.
12. Leinonen ES, Hurt-Camejo E, Wiklund O, Mattson Hultén L, Hiukka A, Taskinen M-R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 387-94.
13. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20: 159-69.
14. World Health Organisation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organisation, 1999.
15. Taskinen M-R. Kuusi T, Helve E, Nikkilä EA, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988; 8: 168-77.
16. Vakkilainen J, Jauhiainen M, Ylitalo K et al. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 2002; 43: 598-603.
17. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000; 85: 4426-33.
18. Leinonen ES, Salonen JT, Salonen RM et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 2002; 25: 1807-12.
19. Temelkova-Kurktschiev TS, Koehler C, Leonhardt W et al. Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care 1999; 22: 333-8.
20. Haffner SM, D'Agostino R Jr, Saad MF et al. Carotid artery atherosclerosis in type 2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000; 85: 1395-400.
21. Goff DC Jr, D'Agostino RB, Haffner S, Saad ME, Wagenknecht LE. for the Insulin Resistance Atherosclerosis Study investigators. Lipoprotein concentrations and carotid atherosclerosis by diabetes status. Results from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2000; 23: 1006-11.
22. Engstrom G, Stavenow L, Hedblad B et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 2003; 52: 442-7.
23. Bannan S, Mansfleld MW, Grant PJ. Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients. Diabetologia 1998; 41: 460-6.
24. Lim SC, Caballero AE, Smakowski P, LoGerfo FW, Horton ES, Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999; 22: 1865-70.
25. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
26. Jager A, van Hinsbergh VWM, Kostense PJ et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8.
27. 7 Jager A, van Hinsberg VW, Kostense PJ et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: The Hoorn Study. Diabetes 2000; 49: 485-91.
28. Stehouwer CDA, Gall M-A, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-65.
29. Blake GJ, Ridker PM. C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002; 22: 1512-3.
30. Biondi-Zoccai GGL, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003; 41: 1071-7.
31. Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 120-7.
32. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002; 144: 233-8.
33. Adams MR, Nakagomi A, Keech A et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995; 92: 2127-34.
34. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. The Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39: 632-7.
35. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-887.
36. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004: 27: S15-S35.
37. Geroulakos G, Ramaswami G, Veller MG et al. Arterial wall changes in type 2 diabetic subjects. Diabet Med 199; 11: 692-5.
38. Yamasaki Y, Kodama M, Nishizawa H et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects. Diabetes Care 2000; 23: 1310-5.
39. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
40. Stratton IM, Adler AI, Neil HAW et alon behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35); observational study. BMJ 2000; 321: 405-12.